Otsuka Precision Health (OPH) and digital health company Amalgam Rx have launched the Elevmi application for individuals with Alzheimer’s disease.
Elevmi is an artificial intelligence (AI)-based intelligent digital application designed for caregivers supporting those with dementia.
According to Otsuka Precision Health, the app enhances caregiver access to information and support using AI for curated and personalised insights.
It also aids dementia caregivers by providing 24/7 support, care coordination, and a better understanding of the patient’s condition.
Otsuka Precision Health president Sanket Shah said: “We realise that caregivers play a critical role in supporting patients with Alzheimer’s and in addition to working on patients focused solutions, we wanted to bring Elevmi to stay true to our mission in supporting the whole person’s care.”
Elevmi offers an intuitive user experience powered by a large language model (LLM). This model is trained on content from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH) and PsychU, an online mental health resource.
The digital solution also helps caregivers manage the individual’s conditions while supporting their mental health and wellness.
With Elevmi’s conversational AI, caregivers can discuss their experiences, ask questions about the patients, prepare for doctor visits, and more.
The app, now available on iOS and Android stores, was designed based on insights from family caregivers of Alzheimer’s patients.
Additionally, caregivers provided ongoing feedback on branding, design, AI responses, and in-app content.
Amalgam Rx CEO Ryan Sysko said: “Our AI platform has been purpose-built with appropriate guardrails for life sciences and other healthcare companies.
“Our collaboration with OPH is a great example of working with our customers to navigate the complexities and responsibly bring real innovation to patients and caregivers.”
OPH is a subsidiary of Otsuka America, the US division of Japan-based Otsuka Pharmaceutical.
Otsuka Precision Health focuses on bringing prescription-based digital therapeutics, and new health technologies. The firm also offers non-promotional patient support services.
AmalgamRx aims to advance care delivery and the chronic care ecosystem to help patients and providers make informed decisions.
Its AI-powered Electronic Health Record (EHR) solutions and SaMD platform enable life sciences companies, health plans, and provider organisations to collaborate for better care.
In late 2022, Amalgam Rx expanded its global agreement with Novo Nordisk for the commercialisation of Dose Check, a digital insulin initiation and titration app.
